Home LiteratureArticle Details
PMID: 12186604 Published · ppublish English Clinical Trial Journal Article Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't

Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock.

JAMA ·Vol. 288 ·No. 7 ·2002-08-21 ·Pages 862-71

Annane D, Sébille V, Charpentier C, Bollaert PE, François B, Korach JM, Capellier G, Cohen Y, Azoulay E, Troché G, Chaumet-Riffaud P, Chaumet-Riffaut P, Bellissant E

Abstract

Septic shock may be associated with relative adrenal insufficiency. Thus, a replacement therapy of low doses of corticosteroids has been proposed to treat septic shock. To assess whether low doses of corticosteroids improve 28-day survival in patients with septic shock and relative adrenal insufficiency. Placebo-controlled, randomized, double-blind, parallel-group trial performed in 19 intensive care units in France from October 9, 1995, to February 23, 1999. Three hundred adult patients who fulfilled usual criteria for septic shock were enrolled after undergoing a short corticotropin test. Patients were randomly assigned to receive either hydrocortisone (50-mg intravenous bolus every 6 hours) and fludrocortisone (50- micro g tablet once daily) (n = 151) or matching placebos (n = 149) for 7 days. Twenty-eight-day survival distribution in patients with relative adrenal insufficiency (nonresponders to the corticotropin test). One patient from the corticosteroid group was excluded from analyses because of consent withdrawal. There were 229 nonresponders to the corticotropin test (placebo, 115; corticosteroids, 114) and 70 responders to the corticotropin test (placebo, 34; corticosteroids, 36). In nonresponders, there were 73 deaths (63%) in the placebo group and 60 deaths (53%) in the corticosteroid group (hazard ratio, 0.67; 95% confidence interval, 0.47-0.95; P =.02). Vasopressor therapy was withdrawn within 28 days in 46 patients (40%) in the placebo group and in 65 patients (57%) in the corticosteroid group (hazard ratio, 1.91; 95% confidence interval, 1.29-2.84; P =.001). There was no significant difference between groups in responders. Adverse events rates were similar in the 2 groups. In our trial, a 7-day treatment with low doses of hydrocortisone and fludrocortisone significantly reduced the risk of death in patients with septic shock and relative adrenal insufficiency without increasing adverse events.

MeSH Terms
Adrenal Insufficiency/complications,diagnosis Anti-Inflammatory Agents/administration & dosage,therapeutic use Double-Blind Method Female Fludrocortisone/administration & dosage,therapeutic use Humans Hydrocortisone/administration & dosage,therapeutic use Male Middle Aged Proportional Hazards Models Severity of Illness Index Shock, Septic/complications,drug therapy,mortality Survival Analysis Vasoconstrictor Agents/therapeutic use
Chemicals
Anti-Inflammatory Agents Vasoconstrictor Agents Fludrocortisone Hydrocortisone
Authors & Affiliations
13 authors, click to expand affiliations / ORCID
Annane Djillali
Service de Réanimation Médicale, Hôpital Raymond Poincaré, 104 Blvd Raymond Poincaré, 92380 Garches, France. djillali.annane@rpc.ap-hop-paris.fr
Sébille Véronique
Charpentier Claire
Bollaert Pierre-Edouard
François Bruno
Korach Jean-Michel
Capellier Gilles
Cohen Yves
Azoulay Elie
Troché Gilles
Chaumet-Riffaud Philippe
Chaumet-Riffaut Philippe
Bellissant Eric
Article Info
Journal
JAMA
Abbr.
JAMA
ISSN
0098-7484
Published
2002-08-21
Pages
862-71
Language
English
Region
United States
NLM ID
7501160
Subset
IM
Corrections
ErratumIn
-
CommentIn
CommentIn
CommentIn
CommentIn
CommentIn
CommentIn
CommentIn
CommentIn
CommentIn
CommentIn
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com